PriceTargets.com logo

NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.38
  • Forecasted Upside: 65.84 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.05 As of 09/23/2021 05:00 PM ET
▲ +0.15 (3.06%)

This chart shows the closing price for CPRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Catalyst Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CPRX

Analyst Price Target is $8.38
▲ +65.84% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Catalyst Pharmaceuticals in the last 3 months. The average price target is $8.38, with a high forecast of $11.00 and a low forecast of $6.50. The average price target represents a 65.84% upside from the last price of $5.05.

This chart shows the closing price for CPRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Catalyst Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2021HC WainwrightReiterated RatingBuy$9.00Medium
8/15/2021Roth CapitalReiterated RatingBuyLow
8/10/2021Piper SandlerBoost Price TargetOverweight$5.50 ➝ $6.50Low
5/12/2021Cantor FitzgeraldBoost Price Target$8.00 ➝ $11.00Medium
3/18/2021Roth CapitalBoost Price TargetBuy$6.50 ➝ $7.00Medium
11/10/2020Piper SandlerLower Price TargetOverweight$6.00 ➝ $5.50Low
8/11/2020Roth CapitalReiterated RatingBuyMedium
8/11/2020Piper SandlerLower Price Target$7.00 ➝ $6.00Low
8/4/2020OppenheimerReiterated RatingBuy$8.00Low
5/13/2020SunTrust BanksLower Price TargetBuy$11.00 ➝ $10.00High
2/14/2020Cantor FitzgeraldBoost Price TargetOverweight$11.00 ➝ $12.00High
12/23/2019HC WainwrightReiterated RatingBuy$9.00Medium
11/13/2019Piper Jaffray CompaniesLower Price Target$8.00 ➝ $7.00High
10/31/2019HC WainwrightReiterated RatingBuy$9.00High
10/9/2019Piper Jaffray CompaniesSet Price TargetBuy$8.00N/A
8/8/2019Cantor FitzgeraldBoost Price Target$10.00 ➝ $12.00Low
8/8/2019SunTrust BanksReiterated RatingBuy$9.00 ➝ $11.00High
5/14/2019HC WainwrightSet Price TargetBuy$9.00High
5/7/2019Cantor FitzgeraldReiterated RatingBuy$10.00High
3/19/2019Cantor FitzgeraldReiterated RatingBuy$10.00Low
12/14/2018HC WainwrightReiterated RatingBuyHigh
12/13/2018Cantor FitzgeraldSet Price TargetBuy$9.00High
12/13/2018Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $7.50Low
11/29/2018OppenheimerSet Price TargetBuy$6.00Low
11/28/2018Cantor FitzgeraldSet Price TargetBuy$8.00High
11/9/2018HC WainwrightReiterated RatingBuy$6.00High
11/8/2018OppenheimerSet Price TargetBuy$6.00High
11/8/2018Cantor FitzgeraldSet Price TargetBuy$8.00High
10/26/2018Cantor FitzgeraldSet Price TargetBuy$8.00Medium
10/16/2018OppenheimerSet Price TargetBuy$6.00Low
10/3/2018Cantor FitzgeraldSet Price TargetBuy$8.00Low
9/21/2018Cantor FitzgeraldInitiated CoverageOverweightHigh
9/20/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$8.00High
9/7/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$5.00Medium
8/22/2018HC WainwrightSet Price TargetBuy$6.00High
8/9/2018OppenheimerSet Price TargetBuy$6.00High
8/9/2018HC WainwrightReiterated RatingBuy$6.00High
7/12/2018OppenheimerInitiated CoverageBuy$6.00High
3/15/2018HC WainwrightReiterated RatingBuy$6.00High
12/21/2017HC WainwrightReiterated RatingBuy$6.00High
12/1/2017Piper Jaffray CompaniesSet Price TargetPositive ➝ Buy$8.00Low
11/29/2017SunTrust BanksReiterated RatingBuy$6.00High
11/10/2017HC WainwrightReiterated RatingBuy$6.00N/A
11/1/2017Roth CapitalSet Price TargetBuy$5.00N/A
10/31/2017SunTrust BanksSet Price TargetBuy$5.00N/A
9/5/2017SunTrust BanksReiterated RatingBuy$5.00High
8/10/2017Roth CapitalSet Price TargetBuy$5.00Low
8/7/2017Piper Jaffray CompaniesSet Price TargetBuy$6.00Low
3/20/2017Roth CapitalSet Price TargetBuy$3.00Low
3/20/2017HC WainwrightReiterated RatingBuy$6.00Low
10/14/2016Roth CapitalReiterated RatingBuy$2.50N/A
10/5/2016Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$4.00N/A
(Data available from 9/24/2016 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2021
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2021

Current Sentiment

  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Catalyst Pharmaceuticals logo
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
Read More

Today's Range

Now: $5.05
Low: $4.89
High: $5.06

50 Day Range

MA: $5.49
Low: $4.85
High: $6.04

52 Week Range

Now: $5.05
Low: $2.88
High: $6.24

Volume

569,655 shs

Average Volume

1,303,154 shs

Market Capitalization

$520.04 million

P/E Ratio

7.21

Dividend Yield

N/A

Beta

1.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Catalyst Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Catalyst Pharmaceuticals in the last twelve months: Cantor Fitzgerald, HC Wainwright, Piper Sandler, Roth Capital, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for CPRX.

What is the current price target for Catalyst Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Catalyst Pharmaceuticals in the last year. Their average twelve-month price target is $8.38, suggesting a possible upside of 65.8%. Cantor Fitzgerald has the highest price target set, predicting CPRX will reach $11.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $6.50 for Catalyst Pharmaceuticals in the next year.
View the latest price targets for CPRX.

What is the current consensus analyst rating for Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CPRX will outperform the market and that investors should add to their positions of Catalyst Pharmaceuticals.
View the latest ratings for CPRX.

What other companies compete with Catalyst Pharmaceuticals?

Other companies that are similar to Catalyst Pharmaceuticals include Nuvation Bio, Amarin, Organogenesis, Xencor, ADC Therapeutics, Deciphera Pharmaceuticals, Trillium Therapeutics, NGM Biopharmaceuticals, MorphoSys, Centessa Pharmaceuticals, IVERIC bio, Prelude Therapeutics, Global Blood Therapeutics, uniQure and Dicerna Pharmaceuticals.

How do I contact Catalyst Pharmaceuticals' investor relations team?

Catalyst Pharmaceuticals' physical mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company's listed phone number is (305) 420-3200 and its investor relations email address is [email protected] The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.